

Application Number: 10/602,456
Balschmidt et al.
Filed: June 23, 2003
Attorney Docket No.: 6460.200-US
Via Facsimile No.: 571-273-8300

RECEIVED
CENTRAL FAX CENTER

JUL 21 2006

AMENDMENTS TO THE CLAIMS

CLAIM LISTING

1. (Currently amended) A pharmaceutical composition for parenteral administration, which comprises a peptide and dimethyl sulfone, wherein the concentration of dimethyl sulfone is from 40 to 400 mM, wherein the peptide is selected from human growth hormone, GLP-1, GLP-2, insulin, Factor VIIa, Factor VIII, erythropoietin (EPO), glucagon, interleukin-2 (IL-2), interferon- α , and interferon- β , or an analogue thereof, or derivative thereof, or derivative of an analogue thereof, and wherein the pharmaceutical composition is for parenteral administration.
2. (Cancelled)
3. (Currently amended) A pharmaceutical composition according to claim 1, wherein amount the concentration of dimethyl sulfone is ~~of~~ from 125 to 350 mM.
4. (Original) A pharmaceutical composition according to claim 1, wherein the composition is a solution.
5. (Original) A pharmaceutical composition according to claim 1, wherein the composition is a suspension.
6. (Original) A pharmaceutical composition according to claim 1, which is suitable for administration by injection or infusion.
7. (Original) A pharmaceutical composition according to claim 6, which is suitable for subcutaneous administration.

Application Number: 10/602,456
Balschmidt et al.
Filed: June 23, 2003
Attorney Docket No.: 6460.200-US
Via Facsimile No.: 571-273-8300

8. (Original) A pharmaceutical composition according to claim 6, which is suitable for intramuscular administration.

9. (Original) A pharmaceutical composition according to claim 6, which is suitable for intravenous administration.

10. (Original) A pharmaceutical composition according to claim 1, which is suitable for pulmonary administration.

11. (Original) A pharmaceutical composition according to claim 1, which is suitable for ophthalmic administration or topical administration.

12. (Cancelled)

13. (Currently amended) A pharmaceutical composition according to claim 1 ~~12~~, wherein the peptide is selected from human insulin ~~or an analogue thereof, or a derivative of human insulin, an analogue of human insulin, or the a derivative of an analogue of~~ human insulin analogue.

14. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is human insulin.

15. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is Asp(B28)-human insulin.

16. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is Lys(B28) Pro(B29)-human insulin.

Application Number: 10/602,456
Balschmidt et al.
Filed: June 23, 2003
Attorney Docket No.: 6460.200-US
Via Facsimile No.: 571-273-8300

17. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is Lys(B3) Glu(B29)-human insulin.

18. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is N^{B29}-tetradecanoyl des (B30)-human insulin.

19. (Original) A pharmaceutical composition according to claim 13, wherein the peptide is Gly(A21) Arg(B31) Arg(B32)-human insulin.

20. (Currently amended) A pharmaceutical composition according to claim 13, wherein the peptide is N^{B29}-lithocholoyl-γ-glutamyl N^{B29}-lithocholoyl-γ-glutamyl des (B30)-human insulin.

21. (Currently amended) A pharmaceutical composition according to claim 1-12, wherein the peptide is Gly(8)-human GLP-1.

22. (Currently amended) A pharmaceutical composition according to claim 1-12, wherein the peptide is Arg(34), N-ε-(γ-Glu(N-α-hexadecanoyl))-Lys(26)-human GLP-1(7-37)OH.

23. (Currently amended) A pharmaceutical composition according to claim 1-12, wherein the peptide is Gly(2)-human GLP-2.